Mucosal immunity to poliovirus
Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material
Our proposed clinical dose of BPC157 was 200 g/person/day, and its equivalent dose in rats was 20 g/kg (converted based on body surface area)
Adjusting to Dosage Increases A key aspect of the tirzepatide journey during weeks 5-8 is the typical progression from the initial 2.5mg starting dose to a therapeutic dose, often 5mg
GLP-1 receptor agonist medications are available as a subcutaneous injection (most products) or as an oral tablet (Rybelsus only, as of April 2026) per their FDA labels